Key facts
- Relation’s last known valuation is $124.7M (Jan 2024).
- It has raised $113.4M; the latest was Later Stage VC ($55.0M) in Dec 2025.
- Notable investors include Khosla Ventures, Tech Nation Group, DCVC, Realm Capital Ventures, Raptor Group — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Relation
- ·The full record, as it builds
Funding rounds
No funding rounds for Relation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Relation
Provider of a biotechnology platform intended to develop medicines for diseases with significant unmet needs. The company offers an innovative Lab-in-the-Loop platform that integrates human genetics, single-cell multi-omics, functional assays, and machine learning, enabling the discovery of novel disease interventions directly from human tissue.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 110
- Website
- relationrx.com/
- Ownership
- Privately Held (backing)
Relation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Relation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Relation in its N-PORT filings yet. We sweep new filings monthly.